Walmart's Two Bets: a Tariff Windfall and a Quiet Health Pivot

Walmart's strategy has two moving parts that investors would do well to treat separately. One involves money the government owes the company. The other involves services the company wants to sell. The tariff refund is a one-off windfall, subject to lawyers, bureaucracy and consumer lawsuits. The health push is a recurring bet on higher-margin revenue. Investors who conflate the two are likely to overestimate the former and underappreciate the latter.

The tariff story is the more dramatic. After the Supreme Court struck down tariffs imposed under the International Emergency Economic Powers Act — an emergency-authority statute that allows the president to levy duties without Congressional approval — in February 2026, the government was forced to return the money it had collected. More than $160 billion changed hands between Washington and importers; by August, about $100 billion had been paid out through the customs portal, which opened in April. Citi's initial analysis projected that Walmart would receive approximately $10.2 billion. That figure is more than four times what Target is owed, reflecting Walmart's scale as an importer.

The trouble is that the CFO's number is markedly smaller. John David Rainey, Walmart's chief financial officer, said during the fiscal 2027 first-quarter earnings call in May that the company expects refunds of roughly $2.4 billion, or less than half of one per cent of its $483 billion in annual US sales. The gap between Citi's $10.2 billion and Mr Rainey's $2.4 billion reflects scope: Citi's estimate appears to include a broader set of duties, while only those levied under the invalidated IEEPA authority are refundable. Section 301 tariffs on Chinese imports and Section 232 duties on steel, aluminium and semiconductors remain in place. A refund on one set of duties is not a rebate on all of them.

Even at $2.4 billion, the refund is material. But Mr Rainey's timing was sober. He called the process "very complex" and said it would "probably not… happen very quickly." Refunds are recognised on the income statement only when received, not when claimed, and the customs agency had to validate more than 15 million individual entries by May. The broader uncertainty is whether the administration will restore tariff levels through separate legal authorities. Treasury Secretary Scott Bessent suggested earlier this year that Section 301 tariffs could return to previous levels by July. The refund is a recovery on past costs, not an insurance policy against future ones.

The political risk is not trivial either. A class-action lawsuit was filed in April by Ohio shoppers alleging that Walmart raised prices in 2025 to pass tariff costs along to customers and now stands to reclaim those same dollars from the government. Nike and Nintendo are facing similar suits. Amazon's chief financial officer has signalled it will "automatically issue refunds" to customers where tariffs were passed through on specific items. Walmart has committed more broadly to using the money for price cuts, calling investment in price "the single best return that we can have on a dollar of capital right now". That is a plausible response to the lawsuit and to the competitive need to retain budget-conscious shoppers. It is also a reminder that tariff refunds are not a free option for shareholder buybacks.

Now for the health story. It has been less dramatic, which is arguably more telling. In April 2024, Walmart shut all 51 of its Walmart Health clinics across five states and ended its virtual-care offering. The physical-clinic model had failed to become profitable. It was a costly lesson in retail health: building medical infrastructure requires clinical expertise, patient-acquisition channels and insurance networks that a discounter does not automatically possess. Walgreens has since closed 140 underperforming VillageMD clinics, well above its original target of 60. The retail-into-healthcare rush has run into gravity.

Walmart's pivot has been to try again with lighter infrastructure. In January 2026 it launched Better Care Services, a digital platform providing curated access to third-party urgent-care and behavioural-health providers, same-day consultations via LillyDirect — Eli Lilly's direct-to-consumer pharmaceutical service — and telehealth at a promotional rate of $15. The platform sits alongside a broader wellness push: price rollbacks on more than 1,000 health-related items, new private labels and pharmacy events at nearly 4,600 locations offering free screenings. The partnerships with brands such as Shapermint, Supergut and Eli Lilly focus on product access rather than facility ownership.

The strategic logic is to capture healthcare spend without bearing healthcare risk. Instead of running clinics, Walmart wants to be the shelf, the platform and the distribution channel for services that other providers deliver. Co-branded Medicare Advantage plans with UnitedHealth and expanding Everyday Health Signals, an AI-driven nutrition tool aimed at health plans and benefits managers, are further steps in this direction. Bain & Company estimates that non-traditional players could capture around 30% of the primary-care market by 2030. Walmart's bet is that it can own a share of that shift through access rather than through ownership.

Whether that works depends on margins. Health services through partnerships carry higher gross margins than grocery, and they deepen the relationship with customers who might otherwise treat Walmart as a transactional stop. But the revenue base is still small relative to $713 billion in total fiscal 2026 sales, and the company has not yet demonstrated that digital health partnerships scale profitably. The earnings picture does not show a separate health revenue line large enough to judge. Fiscal 2026 results have been solid: first-quarter revenue was $165.6 billion, in line with consensus, with EPS of $0.61 versus the expected $0.58. Second-quarter revenue came in at $177.4 billion, slightly above consensus of $175.9 billion, though EPS of $0.68 missed the $0.73 forecast. The underlying business is growing at a steady clip, but health has not yet been a distinct earnings driver.

To be sure, Amazon has spent more aggressively — buying One Medical for $3.9 billion — and CVS has deployed $18.6 billion on Oak Street Health and Signify Health. Walmart's restraint, by comparison, may be a virtue. It avoids the integration risk and write-down exposure that plagues acquisitions in healthcare. The trade-off is that its health position will grow slowly, if at all, while competitors with deeper clinical roots build moats that a platform-only approach cannot easily cross.

The two storylines intersect in one respect: both are about customer retention in a strained economy. Mr Rainey noted that gas-station customers are filling fewer than 10 gallons for the first time since 2022, a sign of stress. The high-income shopper is spending with confidence; the lower-income one is navigating financial distress. Price leadership and affordable health access are two sides of the same strategy. A tariff refund that becomes a price cut reinforces Walmart's core. A health platform that keeps customers in the store reinforces it too.

AInvest's aggregate signal labels Walmart a Buy. That is consistent with the structural case: a dominant discounter whose pricing power, scale and logistics moat allow it to compound earnings even when margins are pressured. The tariff refund adds a one-time boost to the balance sheet; the health partnerships offer a longer-term path to higher-margin revenue. Neither is a transformation by itself. Both matter as part of a strategy that is incremental rather than revolutionary.

The broader lesson for investors is not that Walmart has found a windfall and a cure. It is that the company is learning how to extract value without overreaching. It has been burned by physical clinics and is proceeding more carefully. It is receiving government money it overpaid and is deploying it in ways that serve the core business rather than the balance-sheet engineers. That discipline is unglamorous. It is also what has made Walmart hard to displace.